Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Biomarker-Selected Lung Cancer
NCT01935336Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by University of Colorado Denver. Started Sep 2013; status: completed.
02
Drugs
ponatinib
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01935336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935336.